4.5 million ($27.0 million net of tax) for the three months ended March 31, 2013, primarily composed of integration-related activities, are included in cost of revenues.
Costs of $113.6 million ($68.9 million net of tax) primarily composed of integration-related activities and severance costs, including stock compensation, and $26.7 million ($16.4 million net of tax) primarily composed of professional fees, are included in selling, general and administrative expense in the three months ended March 31, 2013 and 2012, respectively.
The Company recorded a net benefit of $3.5 million ($2.1 million net of tax) within selling, general and administrative expenses for the three months ended March 31, 2013 in conjunction with a final settlement related to the strategic decision to exit various businesses.(5)
Debt redemption costs and write-off of deferred financing fees incurred for the early redemption of senior notes totaled $68.5 million ($41.6 million net of tax) and is included in interest expense in the three months ended March, 31, 2013. (6)
Financing costs include fees related to the amortization of remaining bridge loan fees, commitment fees related to the new credit agreement and interest and fees on the senior notes issued in conjunction with the acquisition of Medco. Costs of $79.5 million ($49.0 million net of tax) are included in interest expense in the three months ended March 31, 2012.(7)
Provision for income taxes includes discrete tax charges $10.6 million for the three months ended March 31, 2013 due to changes in unrecognized tax benefits.(8)
Net income from discontinued operations, net of tax includes $8.0 million ($4.9 million net of tax) of amortization of intangible assets related to the acquisition of Medco for the three months ended March, 31 2013.(9)
Adjusted EPS will exclude amortization of intangible assets.(10)
Adjusted EPS will exclude transaction, integration a
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine technology :1
|SOURCE Express Scripts Holding Company|
Copyright©2012 PR Newswire.
All rights reserved
. Express Scripts to Present at Bank of America Merrill Lynch Conference2
. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 20123
. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)4
. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine5
. Generex Augments Antigen Express Scientific Advisory Board6
. Law Office of Brodsky & Smith, LLC Announces Investigation of SRI Surgical Express, Inc.7
. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 20128
. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic9
. Express Scripts Holding Company Announces Second Quarter 2012 Earnings Conference Call10
. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco11
. Express Scripts Reports Second Quarter Results